These results provide further evidence, that ML3000 inhibits 5-LOX as well as COX-1 and COX-2 in vitro and in animal experiments. The favourable gastrointestinal (GI) tolerability of the compound is believed to be linked to the mechanism of combined 5-LOX and COX-1/2 inhibition of ML3000.
1 Ibuprofen enantiomers and their respective coenzyme A thioesters were tested in human platelets and blood monocytes to determine their selectivity and potency as inhibitors of cyclo-oxygenase activity of prostaglandin endoperoxide synthase-1 (PGHS-1) and PGHS-2. 2 Human blood from volunteers was drawn and allowed to clot at 378C for 1 h in the presence of increasing concentrations of the test compounds (R-ibuprofen, S-ibuprofen, R-ibuprofenoyl-CoA, Sibuprofenoyl-CoA, NS-398). Immunoreactive (ir) thromboxane B 2 (TXB 2 ) concentrations in serum were determined by a speci®c EIA assay as an index of the cyclo-oxygenase activity of platelet PGHS-1. 3 Heparin-treated blood from the same donors was incubated at 378C for 24 h with the same concentrations of the test compounds in the presence of lipopolysaccharide (LPS, 10 mg ml 71 ). The contribution of PGHS-1 was suppressed by pretreatment of the volunteers with aspirin (500 mg; 48 h before venepuncture). As a measure of LPS induced PGHS-2 activity immunoreactive prostaglandin E 2 (irPGE 2 ) plasma concentrations were determined by a speci®c EIA assay. 4 S-ibuprofen inhibited the activity of PGHS-1 (IC 50 2.1 mM) and PGHS-2 (IC 50 1.6 mM) equally. Ribuprofen inhibited PGHS-1 (IC 50 34.9) less potently than S-ibuprofen and showed no inhibition of PGHS-2 up to 250 mM. By contrast R-ibuprofenoyl-CoA thioester inhibited PGE 2 production from LPSstimulated monocytes almost two orders of magnitude more potently than the generation of TXB 2 (IC 50 5.6 vs 219 mM). 5 Western blotting of PGHS-2 after LPS induction of blood monocytes showed a concentrationdependent inhibition of PGHS-2 protein expression by ibuprofenoyl-CoA thioesters. 6 These data con®rm that S-ibuprofen represents the active entity in the racemate with respect to cyclooxygenase activity. More importantly the data suggest a contribution of the R-enantiomer to therapeutic eects not only by chiral inversion to S-ibuprofen but also via inhibition of induction of PGHS-2 mediated by R-ibuprofenoyl-CoA thioester. 7 The data may explain why racemic ibuprofen is ranked as one of the safest non-steroidal antiin¯ammatory drugs (NSAIDs) so far determined in epidemiological studies.
The synthesis of fluorinated derivatives of the sulphide and sulphone metabolites of sulindac, a non‐steroidal anti‐inflammatory agent with chemopreventative activity, is reported.
The key step in the synthesis is a Pummerer‐rearrangement of the parent sulindac sulphoxide using (diethylamino)sulphur trifluoride as an activating agent and as a source of the fluoride nucleophile. The reaction leads to the formation of the 4‐fluoromethylthio and 4‐fluoromethylsulphonyl derivatives of sulindac (4a and 4b, respectively). Sulindac sulphide is 2.5 times more potent as a COX‐1 inhibitor compared with its fluorinated counterpart 4a. The sulphones were inactive as COX‐1 inhibitors, and none of the compounds inhibited COX‐2 concentrations up to 0.1 mM. Cytotoxicity assays showed that 4a and 4b were as cytotoxic as sulindac sulphide and sulindac sulphone on 3719 colorectal carcinoma cell lines. Compound 4b was the most potent compound on RCA cells with an IC50 of 95 μM (sulindac sulphide 140μM, sulindac sulphone 175 μM).
Fluorinated sulindac derivatives warrant further investigation since we have shown that cytotoxic activity can be retained or even increased independently from COX‐inhibitory properties. This could help minimize the undesired side‐effects associated with chronic sulindac administration.
Aims To investigate the pharmacokinetics of the enantiomers of flurbiprofen and inhibition of prostanoid production in blister fluid and serum. Methods Eleven healthy volunteers received 75 mg R-, 75 mg S-flurbiprofen or no medication in a randomized 3-way cross-over study. Flurbiprofen concentrations were determined by h.p.l.c. TXB 2 and PGE 2 were determined by enzyme immunoassay and chemiluminescence immunoassay respectively. Results S-flurbiprofen produced almost complete (>99% vs baseline) inhibition of thromboxane B 2 (TXB 2 ) in serum in all volunteers and significant inhibition of prostaglandin E 2 (PGE 2 ) generation in blister fluid, but there was a considerable inter-individual variation in the response ranging from −78 to +190% change from control PGE 2 AUC. After administration of R-flurbiprofen, there was a mean maximum TXB 2 inhibition of 65.2±15.0% in serum but no significant changes of PGE 2 levels in blister fluid were observed. The pharmacokinetic parameters in serum and blister fluid were not significantly different between enantiomers. R-to S-inversion did not occur to a clinically relevant extent. For R-flurbiprofen, the complex rate constant of transfer into blister fluid was greater at the u.v.-exposed site (0.110±0.050) than at the control site (0.079±0.026, P<0.05) which corresponded to a higher AUC and C max of R-flurbiprofen in u.v.-exposed blister as compared with control. For inhibition of TXB 2 generation after administration of S-flurbiprofen, a sigmoidal log-linear concentration-response relationship was established in all subjects (EC 50 : 0.123±0.092 mg ml −1 ). In contrast, inhibition of PGE 2 production in blister showed no clear concentration-response relationship when correlated with concentrations of S-flurbiprofen in either serum or blister fluid. After administration of R-flurbiprofen, no concentration-effect relationship could be established. Conclusions It is concluded that the blister model may have value for studying the pharmacokinetics and pharmacodynamics of antiinflammatory drugs in humans. Interestingly, inter-individual variation in the pharmacokinetics of flurbiprofen enantiomers could not account for the variability in response observed in the blister model.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.